Today, at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, QIAGEN announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QCI Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research as a Sample to Insight workflow on QIAGEN's GeneReader NGS System.
Meet and talk with our experts at ASH 18, booth #1557!
Featured Products and Solutions
On September 25-29, 2016, the 28th Congress of the European Society of Pathology will take place in Cologne, Germany. For the first time the congress will be arranged as a joined venture with the XXXI International Congress of the International Academy of Pathology.
We're looking forward to meet you there and present QIAGEN Clinical Insights and our solutions for hereditary diseases.
Would you like to know more the GeneReader NGS System and our Sample to Insight solution? You're welcome to join our symposium:
Time and date: September 26 from 1:00 p.m. to 2:30 p.m.
Location: Congress Hall 3
Program:
The new NGS solution to investigate cancer - QIAGEN’s sample to insight approach
Salim Essakali, QIAGEN, Germany
The GeneReader NGS System: experience of a complete NGS workflow solution
Margarethe Odenthal, PD. Dr., Pathology Institute, Universitätsklinikum Cologne, Germany
Qiagen Clinical Insight – Clinical interpretation and reporting of complex NGS data made simple
Ian Cook, Advanced Genomics Clinical Sales Specialist, QIAGEN
Learn more about our hereditary disease solution
Get more details about ESP
The AGBT Precision Health meeting will take place in Scottsdale, Arizona on September 22-24, 2016. We will be there and we hope you'll come visit us at booth #13.
We offer the most comprehensive sample to insight NGS workflow and we're looking forward to tell you much more about it at the AGBT Precision Health meeting. Stop by our booth #13 to learn more about:
Leveraging biological pathways and network analytics to identify disease-causing mutations from clinical genome and exome sequence (CGES) data
Poster #510
Presenter: Sohela Shah, PhD, Genome Scientist, QIAGEN Bioinformatics
Date and time: September 23, 1:30 p.m. - 3:00 p.m.
Learn more about our hereditary disease solution
Get more details about AGBT Precision Health
The European Association for Cancer Research is hosting EACR24 in Manchester, UK on July 9-12, 2016.
We're looking forward to attend the congress and present our solutions. Please visit us at booth D450 and join our session on July 10:
QIAGEN’s new NGS solutions for cancer research – a sample to insight approach
When: Sunday, July 10 at 7 p.m. - 8:30 p.m.
Location: Room Exchange 9
The session will feature data generated with the GeneReader NGS System, new targeted DNA sequencing solutions and a clinical ctDNA study with Biomedical Genomics Workbench. Invited speakers are:
Finger food and refreshments will be provided
We're looking forward to seeing you at EACR!
Learn more about Biomedical Genomics Workbench
Get more details about EACR24
At the AGBT conference in Orlando we announced a new collaboration with 10x Genomics to co-market and co-develop NGS, single-cell biology, and bioinformatics solutions. We believe that 10x Genomics will be innovative collaborators in the advancement of human genetics, and our partnership will unfold in multiple phases.
The collaboration will include an investigation of the implementation of 10x Genomic’ GemCode technology with our GeneReader NGS system. And from a bioinformatics perspective, we’ll also look into enabling the processing and analysis of 10x Genomics’ “Linked-Reads” with our suite of bioinformatics solutions aiming to address the challenges of data analysis, interpretation, clinical decision-support, and reporting that rely on testing for long-range phasing and structural variants in genomics.
We are thrilled to collaborate with 10x Genomics, and we look forward to providing even more comprehensive solutions for our NGS customers.
For more information the collaboration, please read the official press release below.
Press release
QIAGEN and 10x Genomics to enter into co-marketing and co-development collaboration
Multi-phase collaboration to advance next-generation sequencing, single-cell biology, and bioinformatics Sample to Insight solutions
Orlando, Florida, February 9, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration with 10x Genomics to develop and promote comprehensive solutions for next-generation sequencing (NGS), single-cell biology and bioinformatics.
This collaboration includes:
“QIAGEN’s collaboration with 10x Genomics enables both companies to better serve its customers, helping them make groundbreaking advances in single-cell biology, bioinformatics and beyond,” said Peer Schatz, CEO of QIAGEN. “10x Genomics is recognized for delivering critical long-range sequence information that greatly expands the quality of genome research. This partnership will further the potential of each of our product lines while providing significant new capabilities to NGS researchers.”
“We welcome the opportunity to partner with QIAGEN, with their comprehensive offerings for genomic analysis, ranging from sample preparation technologies to bioinformatics solutions for the interpretation and analysis of genomic data,” said Serge Saxonov, 10x’s Chief Executive Officer. “Access to long-range sequence information is becoming the standard for obtaining the most comprehensive understanding of disease, and we expect this collaboration to allow our respective customers to gain valuable insights that have previously not been possible.”
10x Genomics’ GemCode™ Platform overcomes existing NGS limitations through a combination of microfluidics, chemistry and bioinformatics. The system is a unique molecular barcoding and analysis platform that consists of instrumentation, reagents and software to provide a complete approach for a broad range of applications, including single-cell transcriptomics and whole genome analysis.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
It's a pleasure to announce the introduction of our new GeneReader NGS System.
Now, we're offering a complete product suite across all relevant workflow steps – the world’s first truly end-to-end NGS workflow from primary sample to a final report. For more information on the GeneReader NGS System, please read the official press release.
An evaluation of our new GeneReader NGS System has affirmed the performance in detecting gene variants known to be clinically relevant in colorectal cancer.
For more information on the evaluation of our new GeneReader NGS System, please read the official press release below.
Press release
Evaluation confirms: QIAGEN’s new GeneReader NGS System delivers valuable clinical insights
World’s first complete Sample to Insight NGS solution proves equal or better compared with other sequencing workflows and alternative technologies
Austin, Texas, and Hilden, Germany, November 4, 2015 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an evaluation has affirmed the performance of the Company’s GeneReader NGS System in detecting gene variants known to be clinically relevant in colorectal cancer. Results of the analysis, performed by the Broad Institute of MIT and Harvard, a leading biomedical research and sequencing center, will be presented at the Association for Molecular Pathology (AMP) 2015 Annual Meeting on November 4, 2015, in Austin, Texas.
This inquiry is the first assessment of the GeneReader NGS System’s performance in delivering insights on relevant cancer mutations in a laboratory setting. Data from the GeneReader NGS System* compared favorably with QIAGEN’s therascreenRAS mutation tests based on real-time qualitative polymerase chain reaction (PCR) and pyrosequencing, as well as with a next-generation sequencing (NGS) workflow using a competitor’s sequencer. All of the methods were used to test the same 43 tumor samples of confirmed metastatic colorectal cancer from FFPE as sample material.
“Next-generation sequencing can deliver valuable insights for clinical research and diagnostic labs, but users urgently need a simpler, more efficient and cost-effective workflow for NGS technology to enter the mainstream. QIAGEN created the GeneReader NGS System as the first complete Sample to Insight NGS solution designed for any lab to deliver actionable results – and this analysis supports that capability,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “Integrated with the most comprehensive, up-to-date knowledge base through our QIAGEN Clinical Insight software, the GeneReader NGS System is a turnkey solution that is affordable, easy to run – and delivers clinically relevant insights.”
In the analysis, data from the GeneReader NGS System were found to be 100% concordant with results of QIAGEN’s FDA approved therascreen KRAS RGQ PCR assay and the company’s CE-labelled therascreen RAS Extension Pyro Assay. In comparison to these technologies, the GeneReader workflow identified additional aberrations, enabling a more comprehensive investigation of clinically actionable variants (e.g. in the BRAF-gene). Compared to data of the other NGS workflow, which involved an Illumina MiSeq Sequencer, the GeneReader showed 100% positive agreement. Because the data generated by the QIAGEN GeneReader NGS System had fewer FFPE artifacts, it rendered a more accurate reflection of genuine somatic mutations in the samples. For the analysis, the Broad Institute used the Actionable Insights Tumor Panel,the first member of the family of GeneRead QIAact panels powered by QCI®, which was designed with the QIAGEN Knowledge Base to focus only on genes and variants with direct clinical relevance. The panel will be commercially available in the coming weeks.
The QIAGEN Clinical Insight Interpret tool builds on the QIAGEN Knowledge Base and streamlines the creation of a customizable report for each sample based on the test results, with direct links to source information on therapeutic agents, practice guidelines or clinical trials. The comprehensive test report with all the relevant information delivers actionable insights with the highest confidence and efficiency. QIAGEN’s complete NGS solution also includes a software package linking the workflow to a lab’s Laboratory Information System (LIS), enabling tracking of samples and tests, triangulation of NGS data with other results, and a holistic view of each individual case.
“We were pleased with results of the analysis, and optimistic about the System’s potential to deliver accurate and actionable data with high efficiency and low adoption hurdle”, said Dr. Scott Steelman, Associate Director of Technology Labs for the Broad Institute, who led the institute’s analysis of the new NGS workflow.
Commercialization of the QIAGEN GeneReader NGS System will be initiated at the AMP 2015 Annual Meeting, in Austin, Texas, where data from the Broad Institute analysis will be presented in a Corporate Workshop.
Time: November 4, 3:00 - 3:50pm
Speaker: Dr. Scott Steelman, The Broad Institute of MIT and Harvard
Location: Grand Ballroom E, Austin Convention Center, Austin, Texas.
For more information on the GeneReader NGS System, please visit www.GeneReaderNGS.com.
*The current version of the GeneReader NGS System is for Research Use Only
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2015, QIAGEN employed approximately 4,500 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
